Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 35 min ago
Peer-reviewedCC BY-NC 4.0Journal of Pharmaceutical Policy and Practice

Adverse drug reaction reporting by community pharmacists: attitudes, practices, barriers, and facilitators

8 affiliations
  1. 1Department of Clinical Pharmacy, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid, Jordan
  2. 2Department of Pharmacy, Faculty of Pharmacy, Al-Zaytoonah University of Jordan, Amman, Jordan
  3. 3Department of Pharmacy Practice and Pharmacotherapeutics, University of Sharjah, Sharjah, United Arab Emirates
  4. 4College of Pharmacy, Al Ain University, Abu Dhabi, United Arab Emirates
  5. 5Department of Pharmacology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada
  6. 6Department of Medical Sciences, College of Medicine and Health Science, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates
  7. 7Department of Biopharmaceutics and Clinical Pharmacy, School of Pharmacy, The University of Jordan, Amman, Jordan
  8. 8Department of Biomedical and Translational Sciences, Carle Illinois College of Medicine, University of Illinois Urbana-Champaign, Urbana, IL, USA

Abstract

Background: Adverse drug reactions (ADRs) pose a significant threat to public health, increasing morbidity and mortality rates globally. In the UAE, a national pharmacovigilance programme established by the Ministry of Health and Prevention encourages healthcare professionals, including community pharmacists, to report ADRs, although reporting is currently voluntary rather than mandatory. Timely and accurate ADR reporting is essential to enhance patient safety, minimise negative effects, and improve overall healthcare outcomes. Therefore, we aimed to evaluate community pharmacists’ attitudes and practices regarding ADR reporting and to explore the associated barriers and facilitators to provide this service.

Methods: In this cross-sectional study, a validated questionnaire was distributed online to community pharmacists across the UAE via social media platforms, such as Facebook, WhatsApp, and X. The study utilised a custom-designed questionnaire to assess community pharmacists’ attitude, practice, barriers, and facilitators regarding ADR reporting.

Results: A total of 533 pharmacists participated in this study. The median age was 35 years (30–42). The participants had an overall good attitude, but inadequate practice regarding ADR reporting. Lack of time (49%), poor communication with the patient (49%), reporting ADRs of multiple medications (37%), and lack of confidence to discuss ADRs with the prescriber (37%) were the most identified barriers to ADR reporting, while reminders (54%) and empowering patients (53%) were the most commonly suggested facilitators. Female pharmacists had significantly higher attitude than male pharmacists, while pharmacists who had B pharm showed less practice than those holding a post-graduate degree.

Conclusion: Pharmacists should engage in awareness and education campaigns aimed at enhancing their communication skills and increasing their confidence and abilities in reporting ADRs, with a specific emphasis on male and less educated pharmacists. Additionally, the integration of reminders and initiatives that empower patients can help overcome barriers to ADR reporting. These efforts have the potential to enhance medication management and boost patient safety.

Related

  1. Knowledge, attitudes and practices among Australian community pharmacists towards naloxone and overdose prevention: a national cross-sectional study
    Louisa Picco, Monica Jung, Rose Laing +3
    International Journal of Clinical PharmacyPeer-reviewedCC BY 4.0Full textEpidemiology & public healthPMC
  2. Knowledge, Attitudes, and Practices of Malaysian Pharmacists Regarding AI Adoption: Cross-Sectional Study
    Chee Tao Chang, Xin Jie Lim, Jason Choong Yin Lee +7
    JMIR Formative ResearchPeer-reviewedCC BY 4.0Full textEpidemiology & public healthPMC
  3. Sudanese Pharmacists’ Knowledge, Attitudes, Practices, and Barriers Regarding Breast Cancer Endocrine Therapy: A Cross- Sectional Survey
    Tarteel Mohamed Hassan, Alfatih M Alarabi, Rubba Abdelazeim Hussein Eljack +8
    Breast Cancer : Targets and TherapyPeer-reviewedCC BY-NC 4.0Full textPharmacology & toxicologyPMC
  4. Facilitators and barriers to community-based livestock abortion reporting for Rift Valley Fever surveillance in Uganda: A COM-B analysis
    Abel W. Walekhwa, Andrew J.K. Conlan, Lydia N. Namakula +4
    PLOS OnePeer-reviewedCC BY 4.0Full textEpidemiology & public healthInfectious diseasePLOS
  5. Evaluation of a Structured Educational Program for Community Pharmacists' Knowledge, Attitudes, and Satisfaction Toward Diabetes Patient-Centered Care: A Non-Randomized Quasi-Experimental Study.
    Heba Awadallah, Maher Khdour
    Healthcare (Basel, Switzerland)Peer-reviewedCC BYFull textPharmacology & toxicologyEurope PMC
BibTeX
@article{jarab2026adverse,
  title = {{Adverse drug reaction reporting by community pharmacists: attitudes, practices, barriers, and facilitators}},
  author = {Anan S. Jarab and Walid Al-Qerem and Karem H. Alzoubi and Shrouq R. Abu Heshmeh and Hala Kharoub and Osama H. Abusara and Yazid N. Al Hamarneh and Eman Alefishat},
  journal = {Journal of Pharmaceutical Policy and Practice},
  year = {2026},
  month = nov,
  doi = {10.1080/20523211.2026.2749254},
  url = {https://doi.org/10.1080/20523211.2026.2749254},
  note = {CC BY-NC 4.0},
}
RIS
TY  - JOUR
TI  - Adverse drug reaction reporting by community pharmacists: attitudes, practices, barriers, and facilitators
AU  - Anan S. Jarab
AU  - Walid Al-Qerem
AU  - Karem H. Alzoubi
AU  - Shrouq R. Abu Heshmeh
AU  - Hala Kharoub
AU  - Osama H. Abusara
AU  - Yazid N. Al Hamarneh
AU  - Eman Alefishat
PY  - 2026
DA  - 2026/11/09
JO  - Journal of Pharmaceutical Policy and Practice
DO  - 10.1080/20523211.2026.2749254
UR  - https://doi.org/10.1080/20523211.2026.2749254
AB  - Background: Adverse drug reactions (ADRs) pose a significant threat to public health, increasing morbidity and mortality rates globally. In the UAE, a national pharmacovigilance programme established by the Ministry of Health and Prevention encourages healthcare professionals, including community pharmacists, to report ADRs, although reporting is currently voluntary rather than mandatory. Timely and accurate ADR reporting is essential to enhance patient safety, minimise negative effects, and improve overall healthcare outcomes. Therefore, we aimed to evaluate community pharmacists’ attitudes and practices regarding ADR reporting and to explore the associated barriers and facilitators to provide this service.  Methods: In this cross-sectional study, a validated questionnaire was distributed online to community pharmacists across the UAE via social media platforms, such as Facebook, WhatsApp, and X. The study utilised a custom-designed questionnaire to assess community pharmacists’ attitude, practice, barriers, and facilitators regarding ADR reporting.  Results: A total of 533 pharmacists participated in this study. The median age was 35 years (30–42). The participants had an overall good attitude, but inadequate practice regarding ADR reporting. Lack of time (49%), poor communication with the patient (49%), reporting ADRs of multiple medications (37%), and lack of confidence to discuss ADRs with the prescriber (37%) were the most identified barriers to ADR reporting, while reminders (54%) and empowering patients (53%) were the most commonly suggested facilitators. Female pharmacists had significantly higher attitude than male pharmacists, while pharmacists who had B pharm showed less practice than those holding a post-graduate degree.  Conclusion: Pharmacists should engage in awareness and education campaigns aimed at enhancing their communication skills and increasing their confidence and abilities in reporting ADRs, with a specific emphasis on male and less educated pharmacists. Additionally, the integration of reminders and initiatives that empower patients can help overcome barriers to ADR reporting. These efforts have the potential to enhance medication management and boost patient safety.
SN  - 2052-3211
ER  -